SOAT1 and COVID-19: Notably, baricitinib is FDA approved for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19 and thus may also be appropriate to treat kidney-specific inflammatory conditions.80 Thus, our study highlights the JAK-STAT signaling pathway as a promising target for simultaneously mitigating cellular inflammatory stress and APOL1 upregulation across renal cell types.